Otsuka
Japan-headquartered global healthcare group developing and commercializing medicines in neuroscience, oncology, nephrology, cardiovascular disease, and other specialty areas.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Schizophrenia
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationPhase 3 · Recruiting · Attention-deficit/Hyperactivity Disorder
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisPhase 3 · Recruiting · Pulmonary Tuberculosis
A Long-term Trial of EB-1020 in Pediatric Patients With ADHDPhase 3 · Recruiting · Attention-Deficit Hyperactivity Disorder(ADHD)
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute SchizophreniaPhase 3 · Recruiting · Acute Schizophrenia
A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPhase 3 · Recruiting · Phenylketonuria (PKU)
Selected patent records
aripiprazole · Expires 2026-04-28
US 9125939aripiprazole · Expires 2026-07-28
US 7978064aripiprazole · Expires 2026-09-14
US 8759350aripiprazole · Expires 2027-03-02
US 7332472voclosporin · Expires 2027-10-17
US 9444503aripiprazole · Expires 2027-11-19
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/otsuka/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.